Cytokines in the Immunopathology of Systemic Sclerosis

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2015 Jul 9

PMID 26152640

Citations 19

Authors

Jasmin Raja

Christopher Paul Denton

Affiliations

Soon will be listed here.

Abstract

Cytokines and growth factors are key regulators of immune activation, vascular alteration and excessive production of extracellular matrix which are hallmark events in the pathogenesis of systemic sclerosis (SSc). They modulate cell-cell and cell-matrix interactions. In particular, cytokines play a central role in the immunopathogenesis of SSc on the basis of molecular pathways which are complex and not completely understood. The majority of cytokines that may be involved in SSc pathogenesis have effect upon or are derived from cells of the immune system, including both the innate and adaptive compartments. Novel therapies that block key mediators that drive the fibrotic response are being developed and appear as potential therapeutic tools in the treatment of SSc, highlighting the importance for an effective therapy targeted towards the molecular and cellular pathways. This article reviews cytokine biology in that context, with particular emphasis on immunopathology of the disease, therapeutic targeting and the way that current or emerging treatments for SSc might impact on cytokine biology.

Citing Articles

Enhanced Innate and Acquired Immune Responses in Systemic Sclerosis Primary Peripheral Blood Mononuclear Cells (PBMCs).

Szabo I, Badii M, Gaal I, Szabo R, Popp R, Joosten L Int J Mol Sci. 2023; 24(19).

PMID: 37833885 PMC: 10572600. DOI: 10.3390/ijms241914438.

PPARγ partial agonist LPSF/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients.

de Almeida A, Dantas A, de Oliveira Goncalves M, Chene C, Jeljeli M, Chouzenoux S Inflammopharmacology. 2023; 32(1):433-446.

PMID: 37477795 DOI: 10.1007/s10787-023-01296-9.

S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

Svec X, Storkanova H, Trinh-Minh T, Tran M, Storkanova L, Hulejova H Rheumatology (Oxford). 2023; 63(3):817-825.

PMID: 37314987 PMC: 10907816. DOI: 10.1093/rheumatology/kead295.

CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells.

Pietraforte I, Butera A, Gaddini L, Mennella A, Palazzo R, Campanile D Int J Mol Sci. 2023; 24(1).

PMID: 36614095 PMC: 9820649. DOI: 10.3390/ijms24010653.

Paclitaxel-induced diffuse scleroderma with possible scleroderma-renal crisis: a case report and literature review of taxanes-induced scleroderma.

Ketpueak T, Chanloung W, Nan K, Pongsananurak C, Kasitanon N, Louthrenoo W Clin Rheumatol. 2022; 41(12):3887-3896.

PMID: 36085204 PMC: 9462648. DOI: 10.1007/s10067-022-06364-z.

References

Badesch D, Hill N, Burgess G, Rubin L, Barst R, Galie N . Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol. 2007; 34(12):2417-22. View

Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S . Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol. 2000; 278(5):L914-22. DOI: 10.1152/ajplung.2000.278.5.L914. View

Mulligan-Kehoe M, Drinane M, Mollmark J, Casciola-Rosen L, Hummers L, Hall A . Antiangiogenic plasma activity in patients with systemic sclerosis. Arthritis Rheum. 2007; 56(10):3448-58. DOI: 10.1002/art.22861. View

Denton C, Ong V . Targeted therapies for systemic sclerosis. Nat Rev Rheumatol. 2013; 9(8):451-64. DOI: 10.1038/nrrheum.2013.46. View

Steiner M, Preston I . Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag. 2009; 4(5):943-52. PMC: 2605321. DOI: 10.2147/vhrm.s2270. View

DAmelio P, Cristofaro M, DAmico L, Veneziano L, Roato I, Sassi F . Iloprost modulates the immune response in systemic sclerosis. BMC Immunol. 2010; 11:62. PMC: 3018379. DOI: 10.1186/1471-2172-11-62. View

Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y . Defective vasculogenesis in systemic sclerosis. Lancet. 2004; 364(9434):603-10. DOI: 10.1016/S0140-6736(04)16853-0. View

Koch A, Distler O . Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis. Arthritis Res Ther. 2007; 9 Suppl 2:S3. PMC: 2072889. DOI: 10.1186/ar2187. View

Romagnani P, Maggi L, Mazzinghi B, Cosmi L, Lasagni L, Liotta F . CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production. J Allergy Clin Immunol. 2005; 116(6):1372-9. DOI: 10.1016/j.jaci.2005.09.035. View

10.

Trojanowska M . Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford). 2008; 47 Suppl 5:v2-4. DOI: 10.1093/rheumatology/ken265. View

11.

Mouthon L, Berezne A, Bussone G, Noel L, Villiger P, Guillevin L . Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol. 2009; 40(2):84-91. DOI: 10.1007/s12016-009-8191-5. View

12.

Milanetti F, Bucha J, Testori A, Burt R . Autologous hematopoietic stem cell transplantation for systemic sclerosis. Curr Stem Cell Res Ther. 2010; 6(1):16-28. DOI: 10.2174/157488811794480663. View

13.

Ishida W, Mori Y, Lakos G, Sun L, Shan F, Bowes S . Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol. 2006; 126(8):1733-44. DOI: 10.1038/sj.jid.5700303. View

14.

Wolf S, Howat S, Abraham D, Pearson J, Lawson C . Agonistic anti-ICAM-1 antibodies in scleroderma: activation of endothelial pro-inflammatory cascades. Vascul Pharmacol. 2013; 59(1-2):19-26. PMC: 3731553. DOI: 10.1016/j.vph.2013.05.002. View

15.

Eloranta M, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K . Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis. 2010; 69(7):1396-402. DOI: 10.1136/ard.2009.121400. View

16.

Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M . Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010; 14(6A):1241-54. PMC: 3828842. DOI: 10.1111/j.1582-4934.2010.01027.x. View

17.

Denton C, Bickerstaff M, Shiwen X, Carulli M, Haskard D, duBois R . Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol. 1995; 34(11):1048-54. DOI: 10.1093/rheumatology/34.11.1048. View

18.

Udalov S, Dumitrascu R, Pullamsetti S, Al-Tamari H, Weissmann N, Ghofrani H . Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. BMC Pulm Med. 2010; 10:26. PMC: 2881047. DOI: 10.1186/1471-2466-10-26. View

19.

Carvalho D, Savage C, Black C, Pearson J . IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest. 1996; 97(1):111-9. PMC: 507068. DOI: 10.1172/JCI118377. View

20.

Lanteri A, Sobanski V, Langlois C, Lefevre G, Hauspie C, Sanges S . Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev. 2014; 13(9):974-80. DOI: 10.1016/j.autrev.2014.07.003. View